{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:43:49Z","timestamp":1740185029234,"version":"3.37.3"},"reference-count":14,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01DA035714","R01DA047924"],"award-info":[{"award-number":["R01DA035714","R01DA047924"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_nipt-2023-0022_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>HIV-1 Tat (transactivator of transcription) protein disrupts dopaminergic transmission and potentiates the rewarding effects of cocaine. Allosteric modulators of the dopamine transporter (DAT) have been shown to reverse Tat-induced DAT dysfunction. We hypothesized that a novel DAT allosteric modulator, SRI-30827, would counteract Tat-induced potentiation of cocaine reward.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_nipt-2023-0022_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Doxycycline (Dox)-inducible Tat transgenic (iTat-tg) mice and their G-tg\u202f(Tat-null) counterparts were tested in a cocaine conditioned place preference (CPP) paradigm. Mice were treated 14 days with saline, or Dox (100\u202fmg\/kg\/day, i.p.) to induce Tat protein. Upon induction, mice were place conditioned two days with cocaine (10\u202fmg\/kg\/day) after a 1-h daily intracerebroventricular (i.c.v.) pretreatment with SRI-30827 (1\u202fnmol) or a vehicle control, and final place preference assessed as a measure of cocaine reward.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_nipt-2023-0022_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Dox-treatment significantly potentiated cocaine-CPP in iTat-tg\u202fmice over the response of saline-treated control littermates. SRI-30827 treatment eliminated Tat-induced potentiation without altering normal cocaine-CPP in saline-treated mice. Likewise, SRI-30827 did not alter cocaine-CPP in both saline- and Dox-treated G-tg\u202fmice incapable of expressing Tat protein.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_nipt-2023-0022_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings add to a growing body of evidence that allosteric modulation of DAT could provide a promising therapeutic intervention for patients with comorbid HIV-1 and cocaine use disorder (CUD).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/nipt-2023-0022","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T06:20:20Z","timestamp":1701325220000},"page":"1-6","source":"Crossref","is-referenced-by-count":0,"title":["SRI-30827, a novel allosteric modulator of the dopamine transporter, alleviates HIV-1 Tat-induced potentiation of cocaine conditioned place preference in mice"],"prefix":"10.1515","volume":"3","author":[{"given":"Haylee R.","family":"Hammond","sequence":"first","affiliation":[{"name":"Department of Pharmacodynamics , College of Pharmacy, University of Florida , Gainesville , FL 32610 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shainnel O.","family":"Eans","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics , College of Pharmacy, University of Florida , Gainesville , FL 32610 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Cirino","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics , College of Pharmacy, University of Florida , Gainesville , FL 32610 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramaniam","family":"Ananthan","sequence":"additional","affiliation":[{"name":"Department of Chemistry , Drug Discovery Division, Southern Research Institute , Birmingham , AL 35205 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Catya","family":"Jimenez-Torres","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Biomedical Sciences , College of Pharmacy, University of South Carolina , Columbia , SC 29208 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9075-4866","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Biomedical Sciences , College of Pharmacy, University of South Carolina , Columbia , SC 29208 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9851-9342","authenticated-orcid":false,"given":"Jay P.","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics , College of Pharmacy, University of Florida , Gainesville , FL 32610 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"2024032506122249184_j_nipt-2023-0022_ref_001","doi-asserted-by":"crossref","unstructured":"Rumbaugh, JA, Tyor, W. HIV-associated neurocognitive disorders. Neurol Clin Pract 2015;5:224\u201331. https:\/\/doi.org\/10.1212\/cpj.0000000000000117.","DOI":"10.1212\/CPJ.0000000000000117"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_002","doi-asserted-by":"crossref","unstructured":"Purohit, V, Rapaka, R, Shurtleff, D. Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders\/HIV-associated dementia. Mol Neurobiol 2011;44:102\u201310. https:\/\/doi.org\/10.1007\/s12035-011-8195-z.","DOI":"10.1007\/s12035-011-8195-z"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_003","doi-asserted-by":"crossref","unstructured":"Bertrand, SJ, Mactutus, CF, Harrod, SB, Moran, LM, Booze, RM. HIV-1 proteins dysregulate motivational processes and dopamine circuitry. Sci Rep 2018;8:7869. https:\/\/doi.org\/10.1038\/s41598-018-25109-0.","DOI":"10.1038\/s41598-018-25109-0"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_004","doi-asserted-by":"crossref","unstructured":"Midde, NM, Yuan, Y, Quizon, PM, Sun, WL, Huang, X, Zhan, CG, et al.. Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-induced inhibition of dopamine transport. J Neuroimmune Pharmacol 2015;10:122\u201335. https:\/\/doi.org\/10.1007\/s11481-015-9583-3.","DOI":"10.1007\/s11481-015-9583-3"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_005","doi-asserted-by":"crossref","unstructured":"Zhu, J, Ananthan, S, Zhan, C-G. The role of the human dopamine transporter in NeuroAIDS. Pharmacol Ther 2018;183:178\u201389.","DOI":"10.1016\/j.pharmthera.2017.10.007"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_006","doi-asserted-by":"crossref","unstructured":"Zhu, J, Quizon, PM, Wang, Y, Adeniran, CA, Strauss, MJ, Jim\u00e9nez-Torres, AC, et al.. SRI-32743, a novel allosteric modulator, attenuates HIV-1 Tat protein-induced inhibition of the dopamine transporter and alleviates the potentiation of cocaine reward in HIV-1 Tat transgenic mice. Neuropharmacology 2022;220:109239. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109239.","DOI":"10.1016\/j.neuropharm.2022.109239"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_007","doi-asserted-by":"crossref","unstructured":"Sun, WL, Quizon, PM, Yuan, Y, Zhang, W, Ananthan, S, Zhan, CG, et al.. Allosteric modulatory effects of SRI-20041 and SRI-30827 on cocaine and HIV-1 Tat protein binding to human dopamine transporter. Sci Rep 2017;7:3694\u2013706. https:\/\/doi.org\/10.1038\/s41598-017-03771-0. 28623359.","DOI":"10.1038\/s41598-017-03771-0"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_008","doi-asserted-by":"crossref","unstructured":"Kim, BO, Liu, Y, Ruan, Y, Xu, ZC, Schantz, L, He, JJ. Neuropathologies in transgenic mice expressing human immunodeficiency virus Type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol 2003;162:1693\u2013707. https:\/\/doi.org\/10.1016\/s0002-9440(10)64304-0. 12707054.","DOI":"10.1016\/S0002-9440(10)64304-0"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_009","doi-asserted-by":"crossref","unstructured":"Carey, AN, Sypek, EI, Singh, HD, Kaufman, MJ, McLaughlin, JP. Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behav Brain Res 2012;229:48\u201356. https:\/\/doi.org\/10.1016\/j.bbr.2011.12.019.","DOI":"10.1016\/j.bbr.2011.12.019"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_010","doi-asserted-by":"crossref","unstructured":"Xie, Q, Jackson, JE, Barker, JM. The impact of HIV infection in cocaine seeking behaviors. FASEB J 2022;36. https:\/\/doi.org\/10.1096\/fasebj.2022.36.s1.r3811.","DOI":"10.1096\/fasebj.2022.36.S1.R3811"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_011","doi-asserted-by":"crossref","unstructured":"McLaurin, KA, Li, H, Mactutus, CF, Harrod, SB, Booze, RM. Disrupted decision-making: EcoHIV inoculation in cocaine dependent rats. Int J Mol Sci 2022;23:9100. https:\/\/doi.org\/10.3390\/ijms23169100.","DOI":"10.3390\/ijms23169100"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_012","doi-asserted-by":"crossref","unstructured":"Mediouni, S, Jablonski, J, Paris, J, Clementz, M, Thenin-Houssier, S, McLaughlin, J, et al.. Didehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice. Curr HIV Res 2015;13:64\u201379. https:\/\/doi.org\/10.2174\/1570162x13666150121111548.","DOI":"10.2174\/1570162X13666150121111548"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_013","doi-asserted-by":"crossref","unstructured":"Du, Z, Lind, KE, James, TL. Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening. Chem Biol 2002;9:707\u201312. https:\/\/doi.org\/10.1016\/s1074-5521(02)00151-5.","DOI":"10.1016\/S1074-5521(02)00151-5"},{"key":"2024032506122249184_j_nipt-2023-0022_ref_014","doi-asserted-by":"crossref","unstructured":"Haubrich, R, Flexner, C, Lederman, MM, Hirsch, MS, Pettinelli, C, Ginsberg, RS, et al.. A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. J Infect Dis 1995;172:1246\u201352. https:\/\/doi.org\/10.1093\/infdis\/172.5.1246.","DOI":"10.1093\/infdis\/172.5.1246"}],"container-title":["NeuroImmune Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/nipt-2023-0022\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/nipt-2023-0022\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T06:14:01Z","timestamp":1711347241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/nipt-2023-0022\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,11]]},"published-print":{"date-parts":[[2024,3,25]]}},"alternative-id":["10.1515\/nipt-2023-0022"],"URL":"https:\/\/doi.org\/10.1515\/nipt-2023-0022","relation":{},"ISSN":["2750-6665"],"issn-type":[{"type":"electronic","value":"2750-6665"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}